Product claims may differ from country to country based on regulations and product approvals. Please contact your country representative for further details.

»  Búsqueda


Búsqueda avanzada

»  Newsletter

Subscribe to our e-mail newsletter to get our latest news and dates by e-mail

Subscribe / Unsubscribe


Software-Update: Thermo Scientific B·R·A·H·M·S Fast Screen pre I plus V 1.3 for all KRYPTOR systems

Thermo Scientific Biomarkers has brought an Update of the CE marked prenatal screening software B·R·A·H·M·S Fast Screen pre I plus onto the market. The new version 1.3 of the prenatal screening software is available as of November 2011 - currently deliverable in the following languages: German, English and French.


Thermo Scientific Biomarkers launches new assay: Thermo Scientific B·R·A·H·M·S TRAK human KRYPTOR

Thermo Scientific Biomarkers launched the automated TRAK human KRYPTOR assay in countries that accept CE certification. This assay is highly specific for the autoimmune disorder Graves´ disease.


B·R·A·H·M·S-Forum: Workshop on thyroid cancer big success

Hennigsdorf / Berlin 24.11.2009. At the invitation of B·R·A·H·M·S over 50 medics and scientists made their way to Berlin on November 6 and 7 to get an update on most recent developments in the field of thyroid cancer.


Las autoridades en materia de competencia autorizan la absorción de B·R·A·H·M·S por Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) ha comprado todas las acciones de B·R·A·H·M·S Holding GmbH. El acuerdo contractual sobre esta transacción fue anunciado a principios de septiembre. Tras evaluar el acuerdo durante cuatro semanas, las autoridades competentes de supervisión han dado su visto bueno.


The struggle against bacterial resistance and increasing medical costs:

ProHOSP study demonstrates the value of Procalcitonin marker for lower respiratory tract infections


B·R·A·H·M·S y Thermo Fisher Scientific unen sus fuerzas para crear un líder en diagnósticos especializados.

B·R·A·H·M·S anuncia la firma con Thermo Fisher Scientific Inc. (NYSE: TMO) de un Contrato de Compra de Acciones por el 100% del capital social de B·R·A·H·M·S Holding GmbH, con un importe de 330 millones de EUR (aproximadamente 470 millones de USD), incluyendo deuda y otros pasivos. El cierre de la operación, que está sujeta a las autorizaciones reglamentarias aplicables, está previsto para finales de septiembre.


Company Event on Friday, September 4th 2009!


BRAHMS KRYPTOR compact is certified by the Fetal Medicine Foundation (FMF)

Hennigsdorf, Germany, 16-07-2009. The Fetal Medicine Foundation (FMF) confirmed that BRAHMS KRYPTOR compact is fulfilling the requirements for first trimester biochemical screening.


New Cardiac Marker Copeptin accelerates Diagnosis of Acute Myocardial Infarction (AMI)

Hennigsdorf, July 2, 2009. The novel biomarker Copeptin can improve patient management in the Emergency Department (ED). The study “Incremental Value of Copeptin for Rapid Rule Out of Acute Myocardial Infarction (AMI)” was recently published in the Journal of the American College of Cardiology (JACC).

Página : 2